.jpg)
.png)
All
December 18, 2018 Melissa Goetz Lindsey Sutton Co-Presidents Familial Chylomicronemia Syndrome Foundation 7523 Rowena St San Diego, CA 92119 An Open Letter to Familial Chylomicronemia Syndrome... more
The recently published PREDIMED trial is a landmark study assessing the efficacy of a dietary intervention in the primary prevention of cardiovascular disease. The authors used a parallel group design and randomized subjects from multiple centers in Spain. Subjects were men ages 55 to 80 and women... more
Each of us should strive "to rise above the routines of the daily ward round and to see in every patient an opportunity not only to serve mankind in the best tradition of medical excellence, but to add to the store of medical knowledge." –A. McGehee Harvey (1973) Welcome to this... more
.color-blue{ color: #23527c; } Atherosclerotic cardiovascular disease (ASCVD) is a major cause of death and disability worldwide. More than 80% of the global burden of ASCVD occurs in low- and middle-income countries.(1) As a means of attenuating this global epidemic, the concept of... more
The ODYSSEY OUTCOMES trial results, announced today at the American College of Cardiology 67th Annual Scientific Sessions in Orlando, revealed the addition of alirocumab to maximally tolerated statin significantly reduced major adverse cardiovascular events (MACE) compared to those on maximally... more
On December 19, 2024, Ionis Pharmaceuticals, Inc. received FDA approval for TRYNGOLZA (Olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS).
Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are novel, effective oral anti-hyperglycemic medications that inhibit glucose reabsorption in the proximal convoluted tubule of the kidney, independent of insulin, leading to glucosuria and glucose-lowering effects.1 Studies revealed that SGLT2i... more
Membership Services Council The Membership Services Council is focused on enhancing the membership recruitment and retention efforts of the NLA and developing the overall membership value proposition of the association. It serves as an advisory council to the NLA Board... more
Hello NLA members, I hope everyone had a wonderful summer. As our long, warm days move into cool fall nights, the NLA continues to charge ahead, expanding educational opportunities for providers to combat the rise of cardiovascular disease. The fall CLU in Scottsdale, Arizona, will go... more